HER-2/NEU (HER2) ICD MEMORY IMMUNITY AFTER VACCINATION HER2-ICD

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。尽管最近在实体瘤的常规治疗方面取得了进展，但乳腺癌和卵巢癌患者在确定性治疗后可能会因残留的显微镜下病变而复发。根除残留亚临床疾病的一种方法是开发专注于产生肿瘤特异性T细胞免疫的肿瘤疫苗。癌症疫苗研究现在已经证明，患者可以在免疫后产生肿瘤抗原特异性免疫应答。虽然大多数癌症疫苗研究都集中在主动免疫期间产生可测量的免疫力，但很少有研究评估免疫力的持久性或免疫记忆的产生。事实上，对疫苗抗原的免疫记忆的发展将是肿瘤疫苗成功防止复发的关键。因此，我们建议确定先前用HER 2胞内结构域（ICD）DNA疫苗免疫的患者是否对HER 2产生记忆T细胞应答。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Despite recent advances in the conventional treatment of solid tumors, patients with breast and ovarian cancer may relapse after definitive therapy because of residual microscopic disease. One approach to the eradication of residual sub-clinical disease has been the development of tumor vaccines that focus on generating tumor-specific T cell immunity. Cancer vaccine studies have now demonstrated that patients can develop tumor antigen specific immune responses post-immunization. While most cancer vaccine studies have focused on the generation of measurable immunity during active immunization, few studies have evaluated the persistence of immunity or the generation of immunologic memory. Indeed, it is the development of immunologic memory to the vaccinating antigen that would be the key to the success of a tumor vaccine to protect against relapse. Thus, we propose to determine whether patients previously immunized with a HER2 Intracellular Domain (ICD) DNA vaccine develop a memory T cell response to HER2.